Background: Although tobacco exposure is the predominant risk factor for lung cancer, other environmental agents are established lung carcinogens. Measuring the genotoxic effect of environmental exposures remains equivocal, as increases in morbidity and mortality may be attributed to coexposures such as smoking.

Methods: We evaluated genetic instability and risk of lung cancer associated with exposure to environmental agents (e.g., exhaust) and smoking among 500 lung cancer cases and 500 controls using the cytokinesis-blocked micronucleus (CBMN) assay. Linear regression was applied to estimate the adjusted means of the CBMN endpoints (micronuclei and nucleoplasmic bridges). Logistic regression analyses were used to estimate lung cancer risk and to control for potential confounding by age, gender, and smoking.

Results: Cases showed significantly higher levels of micronuclei and nucleoplasmic bridges as compared with controls (mean ± SEM = 3.54 ± 0.04 vs. 1.81 ± 0.04 and mean ± SEM = 4.26 ± 0.03 vs. 0.99 ± 0.03, respectively; P < 0.001) with no differences among participants with or without reported environmental exposure. No differences were observed when stratified by smoking or environmental exposure among cases or controls. A difference in lung cancer risk was observed between nonexposed male and female heavy smokers, although it was not statistically significant (I2 = 64.9%; P value for Q statistic = 0.09).

Conclusions: Our study confirms that the CBMN assay is an accurate predictor of lung cancer and supports the premise that heavy smoking may have an effect on DNA repair capacity and in turn modulate the risk of lung cancer.

Impact: Identifying factors that increase lung cancer risk may lead to more effective prevention measures. Cancer Epidemiol Biomarkers Prev; 22(1); 135–45. ©2012 AACR.

Many occupational and environmental exposures, such as asbestos, arsenic, chromium, radon, and polycyclic aromatic compounds (1) are established lung carcinogens. Assessing genetic instability as a marker of exposure is well documented for these compounds as well as a large number of agents, such as pesticides (2–4), heavy metals (5–8), styrene (9–12), ionizing radiation (13–17), common beauty salon products (18–20), and antineoplastic drugs (21–23). Measuring the genotoxic effect of environmental exposures in humans remains equivocal as increases in morbidity and mortality may also be attributed to coexposures or lifestyle factors, such as smoking and alcohol consumption (24–28).

It is well known that cancer results from the accumulated genetic events that have the potential to be detected cytogenetically (29, 30). Chromosome aberrations are a result of errors in DNA repair in response to exposure to the clastogenic agent (31). The cytokinesis-blocked micronucleus (CBMN) assay in human lymphocytes is one of the most frequently used methods for measuring DNA damage (i.e., chromosome aberrations; ref. 32). The CBMN assay is a multi-endpoint assay that measures not only chromosome damage [i.e., micronuclei reflecting chromosome breaks; nucleoplasmic bridges (NPB) reflecting chromosome rearrangements; and nuclear buds (NBUD) reflecting gene amplification] but also other cellular events (such as apoptosis and necrosis). Compared with other cytogenetic assays, quantification of micronuclei confers several advantages, including speed and ease of analysis, no requirement for metaphase cells and reliable identification of cells that have completed only 1 nuclear division. This prevents confounding effects caused by differences in cell division kinetics because expression of the micronuclei is dependent on completion of nuclear division (33).

We have previously reported that the CBMN assay is a sensitive and specific predictor of lung cancer risk (34, 35), and we further found an increase in lung cancer risk for participants that self-reported exposure to asbestos, fiberglass, wood dust, solvents, bleach, and pesticides (36–38). On the basis of these findings, we conducted the current study to evaluate the extent of genetic instability (using the CBMN assay) in lung cancer cases and controls exposed to environmental agents (namely asbestos, fiberglass, wood dust, solvents, paints, exhaust, and bleach) and the effect of smoking on modulating such genetic instability.

Study population

Lung cancer cases and matched controls in this study were from an ongoing molecular epidemiologic lung cancer risk assessment study at the University of Texas MD Anderson Cancer Center (Houston, TX). Cases (n = 500) were consecutive patients with newly diagnosed, previously untreated, histologically confirmed lung cancer with no age, gender, ethnicity, tumor histology, or disease stage restrictions. Healthy controls (n = 500) were recruited from Kelsey-Seybold Clinics (Houston, TX). Controls were matched to the cases on age (±5 years) and gender. Medical history, family history of cancer, smoking habits, and occupational history were obtained through an interviewer-administered risk-factor questionnaire and by review of an institutional electronic patient history database. Institutional Review Board's approval at both MD Anderson Cancer Center and Kelsey-Seybold was obtained for this study. Upon receiving informed consent, a 10-mL blood sample was drawn into heparinized tubes from all study participants.

Lymphocyte cultures for the CBMN assay

The CBMN assay was conducted using the cytochalasin B technique described by Fenech and Morley (39). Duplicate lymphocyte cultures were prepared for each study subject. Each culture contained 2.0 × 106 cells in 5 mL RPMI-1640 medium supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 10% FBS, and 2 mmol/L l-glutamine (Life Technologies/Invitrogen) and 1% phytohemagglutinin (Remel). At 44 hours after initiation, the cells were blocked in cytokinesis by adding cytochalasin B (Sigma; final concentration 4 μg/mL). The total incubation time for all cultures was 72 hours. After incubation, the cells were fixed in 3:1 methanol:glacial acetic acid, dropped onto clean microscopic slides, air-dried, and stained with Giemsa stain. For each sample, 1,000 binucleated cells were scored blindly using a Nikon E-400 light optical microscope following the scoring criteria and recommendations from The International Collaborative Project on Micronucleus Frequency in Human Populations (HUMN Project) to measure binucleated cells with micronuclei (BN-MN) and binucleated cells with nucleoplasmic bridges (BN-NPB; refs. 40–42).

Exposure assessment

Trained interviewers administered a risk-factor questionnaire through a structured personal interview, and participants were classified as never smokers (smoked fewer than 100 cigarettes in their lifetimes), former smokers (quit more than 1 year before lung cancer diagnosis or interview date), and current smokers. Smoking groups were further categorized into light (pack-years ≤ 20), moderate (20 < pack-years ≤ 40), and heavy (>40 pack-years). Participants were asked to select from a list of environmental exposures (e.g., asbestos, wood dust, pesticides, fiberglass, toluene, fertilizers, diesel fumes, paints, solvents, and exhaust) they may have handled, used, or been in contact with for at least 8 hours a week for a year or more on the job or while working on a hobby. Exposures to asbestos, wood dust, and pesticides were classified by self-report as well as from occupations and industries categorized as having a risk of exposure to these agents. Other exposures such as fibers, benzene, toluene/xylene, dry cleaning fluids, vehicle exhaust, glues, bleach, and plastics were based on the self-reported responses only. In our current study, we focused on the 7 major environmental agents reported by the participants namely: asbestos, fibers, solvents, paints, wood dust, exhaust, and bleach.

Statistical analysis

Pearson χ2 test was used to test for differences between cases and controls for categorical variables: gender, smoking history, environmental exposures (i.e., asbestos, fiber, bleach, wood dust, solvents, paints, and exhaust). Student 2-sample t test was used to test for differences between cases and controls for continuous variables: age and CBMN outcome variables (i.e., BN-MN and BN-NPB). The correlation between the CBMN outcomes was evaluated with Pearson correlation coefficient within cases and controls separately. Principal components analysis (PCA), with the varimax orthogonal method, was used to reduce the number of exposure variables to develop a CBMN outcome exposure score to investigate interaction or effect modification between number of chromosome aberrations and environmental exposures (43). BN-MN and BN-NPB were examined separately for all 7 environmental agents; the 4 modified exposure factors from the PCA (i.e., chemicals, fibers, particulates, and bleach); those with at least 1 of 7 environmental agents; and those without any of the 7 environmental agents. Univariate OR and 95% confidence intervals (CI) were used to estimate the risk of lung cancer. Unconditional multivariable logistic regression analysis was used to control for potential confounding by age, gender, and smoking when appropriate. Linear regression was applied to estimate the adjusted means of the CBMN assay outcomes. Tests for heterogeneity were conducted to evaluate differences in the odds of lung cancer between categories. All statistical tests were 2-sided and P values of 0.05 or less were considered statistically significant. All analyses were conducted using Statistical Analysis System (SAS) software (version 9.2; SAS Institute Inc.).

The study population

Table 1 displays the demographic characteristics of the cases and controls. No statistically significant differences were observed between the cases and controls in terms of age, gender, and environmental exposure. The mean age of cases and controls were 63 (SD ±1.12) years and 62 years (SD ±1.12), respectively (P = 0.31). Fifty-one percent of cases and 46% of controls self-reported at least 1 environmental exposure (P = 0.11). Approximately 84% of the cases were ever smokers as compared with 66% for the controls (P < 0.001). Cases reported significantly heavier smoking histories than controls. When stratified by smoking intensity (i.e., light, moderate, or heavy), approximately 16% of the cases were light smokers, 23% were moderate smokers, and 43% were heavy smokers. For controls, approximately 22% were light smokers, 17% were moderate smokers, and 27% were heavy smokers (P < 0.001). Pack-years of smoking were significantly higher in ever smoker cases as compared with ever smoker controls with 45.5 pack-years compared with 37.5 pack-years, respectively (P < 0.001).

Table 1.

Demographic characteristics by case–control status

Case (N = 500)Control (N = 500)P value*
Age (mean ± SD) 62.50 ± 1.12 61.80 ± 1.12 0.310 
Age group (%) 
 Age ≤ 50 y 80 (16.00) 65 (13.00) 0.209 
 Age > 50 y 420 (84.00) 435 (87.00)  
Gender (%) 
 Male 245 (49.00) 246 (49.20) 0.949 
 Female 255 (51.00) 254 (50.80)  
Smoking (%) 
 Never smokers 91 (18.20) 171 (34.20) <0.001 
 Ever smokers 409 (84.00) 329 (65.80)  
  Smoking intensitya (%) 
   Light (0 < pack-years ≤ 20) 79 (15.80) 109 (21.80) <0.001 
   Moderate (20 < pack-years ≤ 40) 117 (23.40) 86 (17.20)  
   Heavy (40 < pack-years) 213 (42.60) 134 (26.80)  
Smoking pack-yearsb (mean ± SE) 45.56 ± 1.43 37.53 ± 1.58 <0.001 
Environmental exposurec (%) 
 Without environmental exposure 243 (48.60) 269 (53.80) 0.114 
 With at least 1 environmental exposure 257 (51.40) 231 (46.20)  
Case (N = 500)Control (N = 500)P value*
Age (mean ± SD) 62.50 ± 1.12 61.80 ± 1.12 0.310 
Age group (%) 
 Age ≤ 50 y 80 (16.00) 65 (13.00) 0.209 
 Age > 50 y 420 (84.00) 435 (87.00)  
Gender (%) 
 Male 245 (49.00) 246 (49.20) 0.949 
 Female 255 (51.00) 254 (50.80)  
Smoking (%) 
 Never smokers 91 (18.20) 171 (34.20) <0.001 
 Ever smokers 409 (84.00) 329 (65.80)  
  Smoking intensitya (%) 
   Light (0 < pack-years ≤ 20) 79 (15.80) 109 (21.80) <0.001 
   Moderate (20 < pack-years ≤ 40) 117 (23.40) 86 (17.20)  
   Heavy (40 < pack-years) 213 (42.60) 134 (26.80)  
Smoking pack-yearsb (mean ± SE) 45.56 ± 1.43 37.53 ± 1.58 <0.001 
Environmental exposurec (%) 
 Without environmental exposure 243 (48.60) 269 (53.80) 0.114 
 With at least 1 environmental exposure 257 (51.40) 231 (46.20)  

*P values were obtained from Pearson χ2 test (categorical variables) and the Student 2-sample t test (continuous variables).

aSmoking intensity, light smokers (0 < pack-years ≤ 20), moderate smokers (20 < pack-years ≤ 40), heavy smokers (40 < pack-years).

bSmoking pack-years, years smoked times the average number of cigarettes per day divided by 20.

cSelf-reported exposure to at least 1 of 7 environmental agents (i.e., asbestos, fiberglass, wood dust, solvents, paints, exhaust, and bleach).

For exposure to the environmental agents (i.e., asbestos, fiber, bleach, sawdust, solvents, paints, and exhaust), 53% of participants self-reported no environmental exposure, 23% reported 1 of 7 environmental exposures, 10.5% reported 2 of 7 environmental exposures, and 13.5% reported 3 or more of the environmental exposures. Asbestos (19%) and solvents (18%) were the 2 most self-reported environmental exposures followed by exhaust (16%), paints (13.5%), bleach (13%), wood dust (12%), and fiberglass (8.5%).

Genetic instability by smoking and environmental exposure

We analyzed exposure separately for (i) all 7 environmental agents; (ii) as modified exposure categories based on factors from the PCA (i.e., chemicals, fibers, particulates, and bleach); and (iii) as those with at least 1 of 7 environmental agents. We did not find statistically significant differences in chromosome damage for those without environmental exposure or with exposure to any of the 3 exposure categories. Because of sample size, we used those with at least 1 of 7 environmental exposures as the final environmental exposure category in our analyses.

Table 2 presents the distribution of the CBMN outcomes for all cases and controls stratified by smoking and self-reported environmental exposure to at least 1 of 7 environmental agents. Overall cases showed significantly higher levels of genetic instability (BN-MN mean ± SEM = 3.54 ± 0.04; BN-NPB mean ± SEM = 4.26 ± 0.03) as compared with controls (BN-MN mean ± SEM = 1.81 ± 0.04; BN-NPB mean ± SEM = 0.99 ± 0.03; P < 0.001). Among the cases, no statistically significant differences were observed when data were stratified by smoking (BN-MN: Ptrend = 0.69; BN-NPB: Ptrend = 0.89) or environmental exposure (BN-MN: P = 0.24; BN-NPB: P = 0.89); nor for controls by smoking (BN-MN: Ptrend = 0.95; BN-NPB: Ptrend = 0.75). Similarly, among the controls, no significant differences were observed when stratified by environmental exposure BN-MN (P = 0.85), however, a borderline significant difference was observed for those without exposure (BN-NPB mean ± SEM = 1.05 ± 0.04) compared with those with at least 1 environmental exposure (BN-NPB mean ± SEM = 0.94 ± 0.04; P = 0.06). In addition, among the cases, we did not observe significant differences in the micronuclei and NPBs distribution when stratified by tumor histology, or disease stage, thus reducing the probability of this being a disease marker (data not shown).

Table 2.

CBMN outcomes for all cases and controls by smokinga and environmental exposureb

ALLCase (N = 500)P valueControl (N = 500)P value
BN-MN 
 Overall 3.54 ± 0.04  1.81 ± 0.04 <0.001 
 Smokinga 
  Never smoker 3.56 ± 0.10  1.83 ± 0.07  
  Light smokers 3.42 ± 0.11  1.76 ± 0.08  
  Moderate smokers 3.60 ± 0.09  1.77 ± 0.09  
  Heavy smokers 3.53 ± 0.07  1.84 ± 0.08  
  Ptrend = 0.69  Ptrend = 0.95 
 Environmental exposureb 
  Without exposure 3.58 ± 0.07 0.24 1.79 ± 0.06 0.85 
  With at least 1 exposure 3.48 ± 0.11  1.81 ± 0.06  
BN-NPB 
 Overall 4.26 ± 0.03  0.99 ± 0.03 <0.001 
 Smokinga 
  Never smoker 4.20 ± 0.08  0.99 ± 0.05  
  Light smokers 4.37 ± 0.09  0.97 ± 0.06  
  Moderate smokers 4.20 ± 0.07  1.04 ± 0.07  
  Heavy smokers 4.27 ± 0.05  0.98 ± 0.06  
  Ptrend = 0.89  Ptrend = 0.75 
Environmental exposureb 
 Without exposure 4.31 ± 0.05 0.17 1.05 ± 0.04 0.06 
 With at least 1 exposure 4.21 ± 0.05  0.94 ± 0.04  
ALLCase (N = 500)P valueControl (N = 500)P value
BN-MN 
 Overall 3.54 ± 0.04  1.81 ± 0.04 <0.001 
 Smokinga 
  Never smoker 3.56 ± 0.10  1.83 ± 0.07  
  Light smokers 3.42 ± 0.11  1.76 ± 0.08  
  Moderate smokers 3.60 ± 0.09  1.77 ± 0.09  
  Heavy smokers 3.53 ± 0.07  1.84 ± 0.08  
  Ptrend = 0.69  Ptrend = 0.95 
 Environmental exposureb 
  Without exposure 3.58 ± 0.07 0.24 1.79 ± 0.06 0.85 
  With at least 1 exposure 3.48 ± 0.11  1.81 ± 0.06  
BN-NPB 
 Overall 4.26 ± 0.03  0.99 ± 0.03 <0.001 
 Smokinga 
  Never smoker 4.20 ± 0.08  0.99 ± 0.05  
  Light smokers 4.37 ± 0.09  0.97 ± 0.06  
  Moderate smokers 4.20 ± 0.07  1.04 ± 0.07  
  Heavy smokers 4.27 ± 0.05  0.98 ± 0.06  
  Ptrend = 0.89  Ptrend = 0.75 
Environmental exposureb 
 Without exposure 4.31 ± 0.05 0.17 1.05 ± 0.04 0.06 
 With at least 1 exposure 4.21 ± 0.05  0.94 ± 0.04  

aSmoking intensity, light smokers (0 < pack-years ≤ 20), moderate smokers (20 < pack-years ≤ 40), heavy smokers (40 < pack-years); means adjusted by age, gender, and environmental exposures.

bSelf-reported exposure to at least 1 of 7 environmental exposures (i.e., asbestos, fiberglass, wood dust, solvents, paints, exhaust, and bleach; means adjusted by age, gender, and smoking.

To ensure quality control, 20% of the slides were randomly selected for blind rescoring and the intraclass correlation (ICC) was ICC = 0.96 and ICC = 0.97 for the micronuclei and the NPBs, respectively, thus indicating that the agreement between the original and the rescored data were not attributed to random chance.

Genetic instability by gender

Table 3 displays the distribution of CBMN outcomes among males stratified by smoking and self-reported environmental exposure. Male cases showed significantly higher levels of genetic instability (BN-MN mean ± SEM = 3.52 ± 0.06; BN-NPB mean ± SEM = 4.29 ± 0.05) as compared with controls (BN-MN mean ± SEM = 1.83 ± 0.05; BN-NPB mean ± SEM = 0.98 ± 0.04). There was a marginal statistically significant difference in the BN-MN among male cases stratified by smoking (Ptrend = 0.07). No statistically significant differences in BN-MN or BN-NPB were observed among males when stratified by environmental exposure. Similarly, no significant findings were observed among male controls when stratified by smoking or environmental exposure.

Table 3.

CBMN outcomes for male cases and controls by smokinga and environmental exposureb

MalesCase (N = 500)P valueControl (N = 500)P value
BN-MN 
 Overall 3.52 ± 0.06  1.83 ± 0.05 <0.001 
 Smokinga 
  Never smoker 3.35 ± 0.17  1.85 ± 0.11  
  Light smokers 3.31 ± 0.17  1.92 ± 0.12  
  Moderate smokers 3.82 ± 0.13  1.65 ± 0.13  
  Heavy smokers 3.50 ± 0.09  1.85 ± 0.09  
  Ptrend = 0.07  Ptrend = 0.38 
Environmental exposureb 
 Without exposure 3.49 ± 0.11 0.93 1.87 ± 0.09 0.45 
 With exposure 3.50 ± 0.09  1.78 ± 0.07  
BN-NPB 
 Overall 4.29 ± 0.05 0.98 ± 0.04  <0.001 
 Smokinga 
  Never smoker 4.12 ± 0.13  0.90 ± 0.08  
  Light smokers 4.48 ± 0.13  0.89 ± 0.08  
  Moderate smokers 4.24 ± 0.10  1.04 ± 0.09  
  Heavy smokers 4.30 ± 0.07  1.05 ± 0.07  
  Ptrend = 0.71  Ptrend = 0.07 
Environmental exposureb 
 Without exposure 4.30 ± 0.08 0.82 1.03 ± 0.09 0.22 
 With at least 1 exposure 4.27 ± 0.07  0.93 ± 0.05  
MalesCase (N = 500)P valueControl (N = 500)P value
BN-MN 
 Overall 3.52 ± 0.06  1.83 ± 0.05 <0.001 
 Smokinga 
  Never smoker 3.35 ± 0.17  1.85 ± 0.11  
  Light smokers 3.31 ± 0.17  1.92 ± 0.12  
  Moderate smokers 3.82 ± 0.13  1.65 ± 0.13  
  Heavy smokers 3.50 ± 0.09  1.85 ± 0.09  
  Ptrend = 0.07  Ptrend = 0.38 
Environmental exposureb 
 Without exposure 3.49 ± 0.11 0.93 1.87 ± 0.09 0.45 
 With exposure 3.50 ± 0.09  1.78 ± 0.07  
BN-NPB 
 Overall 4.29 ± 0.05 0.98 ± 0.04  <0.001 
 Smokinga 
  Never smoker 4.12 ± 0.13  0.90 ± 0.08  
  Light smokers 4.48 ± 0.13  0.89 ± 0.08  
  Moderate smokers 4.24 ± 0.10  1.04 ± 0.09  
  Heavy smokers 4.30 ± 0.07  1.05 ± 0.07  
  Ptrend = 0.71  Ptrend = 0.07 
Environmental exposureb 
 Without exposure 4.30 ± 0.08 0.82 1.03 ± 0.09 0.22 
 With at least 1 exposure 4.27 ± 0.07  0.93 ± 0.05  

aSmoking intensity, light smokers (0 < pack-years ≤ 20), moderate smokers (20 < pack-years ≤ 40), heavy smokers (40 < pack-years); means adjusted by age and environmental exposures.

bSelf-reported exposure to at least 1 of 7 environmental exposures (i.e., asbestos, fiberglass, wood dust, solvents, paints, exhaust, and bleach; means adjusted by age and smoking intensity.

Table 4 presents the distribution of CBMN outcomes for female cases and controls stratified by smoking and self-reported environmental exposure. Overall female cases displayed significantly higher levels of genetic instability (BN-MN mean ± SEM = 3.55 ± 0.06; BN-NPB mean ± SEM = 4.23 ± 0.05) as compared with controls (BN-MN mean ± SEM = 1.79 ± 0.05; BN-NPB mean ± SEM = 1.01 ± 0.04). No differences were observed among female cases stratified by smoking (BN-MN: Ptrend = 0.42; BN-NPB: Ptrend = 0.73) and marginal statistical significance when stratified by environmental exposure (BN-MN: P = 0.08; BN-NPB: P = 0.08). As with male controls, there were no statistically significant observations among the female controls when stratified by smoking or environmental exposure.

Table 4.

CBMN outcomes for female cases and controls by smokinga and environmental exposureb

FemalesCase (N = 500)P valueControl (N = 500)P value
MN-BN 
 Overall 3.55 ± 0.06  1.79 ± 0.05 <0.001 
 Smokinga 
  Never smoker 3.69 ± 0.13  1.81 ± 0.08  
  Light smokers 3.51 ± 0.14  1.61 ± 0.11  
  Moderate smokers 3.41 ± 0.12  1.89 ± 0.13  
  Heavy smokers 3.58 ± 0.11  1.85 ± 0.12  
  Ptrend = 0.42  Ptrend = 0.27 
Environmental exposureb 
 Without exposure 3.63 ± 0.08 0.08 1.75 ± 0.07 0.26 
 With at least 1 exposure 3.41 ± 0.10  1.88 ± 0.09  
NPB-BN 
 Overall 4.23 ± 0.05  1.01 ± 0.04 <0.001 
 Smokinga 
  Never smoker 4.24 ± 0.08  1.04 ± 0.06  
  Light smokers 4.28 ± 0.09  1.05 ± 0.09  
  Moderate smokers 4.16 ± 0.07  1.03 ± 0.01  
  Heavy smokers 4.25 ± 0.05  0.86 ± 0.09  
  Ptrend = 0.73  Ptrend = 0.13 
Environmental exposureb 
 Without exposure 4.30 ± 0.06 0.08 1.04 ± 0.05 0.18 
 With at least 1 exposure 4.12 ± 0.08  0.92 ± 0.07  
FemalesCase (N = 500)P valueControl (N = 500)P value
MN-BN 
 Overall 3.55 ± 0.06  1.79 ± 0.05 <0.001 
 Smokinga 
  Never smoker 3.69 ± 0.13  1.81 ± 0.08  
  Light smokers 3.51 ± 0.14  1.61 ± 0.11  
  Moderate smokers 3.41 ± 0.12  1.89 ± 0.13  
  Heavy smokers 3.58 ± 0.11  1.85 ± 0.12  
  Ptrend = 0.42  Ptrend = 0.27 
Environmental exposureb 
 Without exposure 3.63 ± 0.08 0.08 1.75 ± 0.07 0.26 
 With at least 1 exposure 3.41 ± 0.10  1.88 ± 0.09  
NPB-BN 
 Overall 4.23 ± 0.05  1.01 ± 0.04 <0.001 
 Smokinga 
  Never smoker 4.24 ± 0.08  1.04 ± 0.06  
  Light smokers 4.28 ± 0.09  1.05 ± 0.09  
  Moderate smokers 4.16 ± 0.07  1.03 ± 0.01  
  Heavy smokers 4.25 ± 0.05  0.86 ± 0.09  
  Ptrend = 0.73  Ptrend = 0.13 
Environmental exposureb 
 Without exposure 4.30 ± 0.06 0.08 1.04 ± 0.05 0.18 
 With at least 1 exposure 4.12 ± 0.08  0.92 ± 0.07  

aSmoking intensity, light smokers (0 < pack-years ≤ 20), moderate smokers (20 < pack-years ≤ 40), heavy smokers (40 < pack-years); means adjusted by age and environmental exposures.

bSelf-reported exposure to at least 1 of 7 environmental exposures (i.e., asbestos, fiberglass, wood dust, solvents, paints, exhaust, and bleach; means adjusted by age and smoking intensity.

Risk of lung cancer associated with smoking and environmental exposure

Table 5 presents the OR and 95% CI associated with smoking and self-reporting environmental exposure. Both moderate and heavy smoking was associated with an increased risk for lung cancer regardless of exposure status: risk for lung cancer in absence of an environmental exposure (light smokers: OR = 1.07, 95% CI, 0.64–1.78; moderate smokers: OR = 2.60, 95% CI, 1.55–4.35; and heavy smokers: OR = 3.05, 95% CI, 1.82–4.85; Ptrend < 0.001) and those with environmental exposure (light smokers: OR = 0.93, 95% CI, 0.54–1.60; moderate smokers: OR = 2.56, 95% CI, 1.55–4.21; and heavy smokers: OR = 3.15, 95% CI, 2.03–4.89; Ptrend < 0.001).

Table 5.

ORs and 95% CIs for smokinga and environmental exposuresb and lung cancer risk

AllcCase (N = 500)Control (N = 500)OR (95% CI)
Without exposure 
 Never smoker 61 (12.20) 111 (22.20) 1.00 (Referent) 
 Light smokers 37 (7.40) 63 (12.60) 1.07 (0.64–1.78) 
 Moderate smokers 55 (11.00) 39 (7.80) 2.60 (1.55–4.35) 
 Heavy smokers 90 (18.00) 56 (11.20) 3.05 (1.82–4.85) 
   Ptrend < 0.001 
With exposure 
 Never smoker 30 (6.00) 60 (12.00) 0.93 (0.54–1.60) 
 Light smokers 42 (8.40) 46 (9.20) 1.78 (1.05–3.02) 
 Moderate smokers 62 (12.40) 47 (9.40) 2.56 (1.55–4.21) 
 Heavy smokers 123 (24.60) 78 (15.60) 3.15 (2.03–4.89) 
   Ptrend < 0.001 
MalesdCase (N = 245)Control (N = 246)OR (95%CI)
Without exposure 
 Never smoker 21 (8.57) 34 (13.82) 1.00 (Referent) 
 Light smokers 10 (4.08) 22 (8.94) 0.74 (0.29–1.86) 
 Moderate smokers 20 (8.16) 14 (5.69) 2.31 (0.96–5.53) 
 Heavy smokers 36 (14.69) 31 (12.60) 1.86 (0.90–3.88) 
   Ptrend = 0.081 
With exposure 
 Never smoker 12 (4.90) 28 (11.38) 0.70 (0.29–1.66) 
 Light smokers 23 (9.39) 31 (12.60) 1.20 (0.56–2.58) 
 Moderate smokers 33 (13.47) 32 (13.01) 1.67 (0.80–3.46) 
 Heavy smokers 90 (36.73) 54 (21.95) 2.68 (1.41–5.11) 
   Ptrend < 0.001 
FemalesdCase (N = 255)Control (N = 254)OR (95% CI)
Without exposure 
 Never smoker 40 (15.69) 77 (30.31) 1.00 (Referent) 
 Light smokers 27 (10.59) 41 (16.14) 1.26 (0.68–2.35) 
 Moderate smokers 35 (13.73) 25 (9.84) 2.68 (1.41–5.09) 
 Heavy smokers 54 (21.18) 25 (9.84) 4.25 (2.30–7.88) 
   Ptrend < 0.001 
With exposure 
 Never smoker 18 (7.06) 32 (12.60) 1.07 (0.53–2.14) 
 Light smokers 19 (7.45) 15 (5.91) 2.44 (0.12–5.30) 
 Moderate smokers 29 (11.37) 15 (5.91) 3.71 (1.78–7.70) 
 Heavy smokers 33 (12.94) 24 (9.45) 2.67 (1.39–5.11) 
   Ptrend = 0.027 
AllcCase (N = 500)Control (N = 500)OR (95% CI)
Without exposure 
 Never smoker 61 (12.20) 111 (22.20) 1.00 (Referent) 
 Light smokers 37 (7.40) 63 (12.60) 1.07 (0.64–1.78) 
 Moderate smokers 55 (11.00) 39 (7.80) 2.60 (1.55–4.35) 
 Heavy smokers 90 (18.00) 56 (11.20) 3.05 (1.82–4.85) 
   Ptrend < 0.001 
With exposure 
 Never smoker 30 (6.00) 60 (12.00) 0.93 (0.54–1.60) 
 Light smokers 42 (8.40) 46 (9.20) 1.78 (1.05–3.02) 
 Moderate smokers 62 (12.40) 47 (9.40) 2.56 (1.55–4.21) 
 Heavy smokers 123 (24.60) 78 (15.60) 3.15 (2.03–4.89) 
   Ptrend < 0.001 
MalesdCase (N = 245)Control (N = 246)OR (95%CI)
Without exposure 
 Never smoker 21 (8.57) 34 (13.82) 1.00 (Referent) 
 Light smokers 10 (4.08) 22 (8.94) 0.74 (0.29–1.86) 
 Moderate smokers 20 (8.16) 14 (5.69) 2.31 (0.96–5.53) 
 Heavy smokers 36 (14.69) 31 (12.60) 1.86 (0.90–3.88) 
   Ptrend = 0.081 
With exposure 
 Never smoker 12 (4.90) 28 (11.38) 0.70 (0.29–1.66) 
 Light smokers 23 (9.39) 31 (12.60) 1.20 (0.56–2.58) 
 Moderate smokers 33 (13.47) 32 (13.01) 1.67 (0.80–3.46) 
 Heavy smokers 90 (36.73) 54 (21.95) 2.68 (1.41–5.11) 
   Ptrend < 0.001 
FemalesdCase (N = 255)Control (N = 254)OR (95% CI)
Without exposure 
 Never smoker 40 (15.69) 77 (30.31) 1.00 (Referent) 
 Light smokers 27 (10.59) 41 (16.14) 1.26 (0.68–2.35) 
 Moderate smokers 35 (13.73) 25 (9.84) 2.68 (1.41–5.09) 
 Heavy smokers 54 (21.18) 25 (9.84) 4.25 (2.30–7.88) 
   Ptrend < 0.001 
With exposure 
 Never smoker 18 (7.06) 32 (12.60) 1.07 (0.53–2.14) 
 Light smokers 19 (7.45) 15 (5.91) 2.44 (0.12–5.30) 
 Moderate smokers 29 (11.37) 15 (5.91) 3.71 (1.78–7.70) 
 Heavy smokers 33 (12.94) 24 (9.45) 2.67 (1.39–5.11) 
   Ptrend = 0.027 

aSmoking intensity, light smokers (0 < pack-years ≤ 20), moderate smokers (20 < pack-years ≤ 40), heavy smokers (40 < pack-years).

bSelf-reported exposure to at least 1 of 7 environmental exposures (i.e., asbestos, fiberglass, wood dust, solvents, paints, exhaust, and bleach.

cModel adjusted by age and gender.

dModel adjusted by age.

Gender differences

When stratified by gender, male heavy smokers with environmental exposure had a nearly 3-fold increased risk of lung cancer (OR = 2.68; 95% CI, 1.41–5.11) as compared with male light (OR = 1.20; 95% CI, 0.56–2.58) and male moderate smokers (OR = 1.67; 95% CI, 0.80–3.46; Ptrend < 0.001). Interestingly, males without a history of environmental exposure showed a borderline risk for lung cancer when stratified by smoking; however, these findings were not statistically significant (Table 5).

Among females without an environmental exposure, we observed an increased risk of lung cancer in association with smoking (light smokers: OR = 1.26, 95% CI, 0.68–2.35; moderate smokers: OR = 2.68, 95% CI, 1.41–5.09; and heavy smokers: OR = 4.25, 95% CI, 2.30–7.88; Ptrend < 0.001). Similar observations were noted among female light and moderate smokers with environmental exposure. In contrast, we found an inverse relationship with female heavy smokers with environmental exposure. Although female heavy smokers in this group had an increased risk of lung cancer (OR = 2.67; 95% CI, 1.39–5.11), the risk was lower than exposed female moderate smokers (OR = 3.71; 95% CI, 1.78–7.70; Ptrend = 0.27; Table 4). We evaluated possible heterogeneity between these observed risks using the Q statistic and associated I2 value (44) and observed no significant heterogeneity between observed risks of lung cancer of female heavy smokers with and without exposure (I2 = 4.4%; P value for Q statistic = 0.31).

When comparing both genders, we observed no difference between nonexposed male and female moderate smokers (OR = 2.31; 95% CI, 0.96–5.53; OR = 2.68; 95% CI, 1.41–5.11, respectively); yet there was a difference between nonexposed male and female heavy smokers (OR = 1.86; 95% CI, 0.90–3.88; OR = 4.25; 95% CI, 2.30–5.11, respectively). Upon evaluation of heterogeneity, we found a borderline significant (I2 = 64.9%; P value for Q statistic = 0.09) level of heterogeneity between these 2 subgroups.

In this study, we evaluated the extent of genetic instability associated with exposure to environmental agents and smoking among lung cancer cases and controls using the CBMN assay. We previously reported that the CBMN assay is a sensitive predictor of lung cancer risk (34, 35). Our current study confirms our previous findings in a larger well-designed case–control study that included never smokers and further stratified by smoking intensity (i.e., light, moderate, and heavy).

Although we did not find significant differences in chromosomal damage in cases or controls with or without environmental exposure, the mean levels of chromosomal damage were higher in cases, even after adjusting for age, gender, and smoking. The observed genetic damage was persistently higher in cases after further stratification by gender and adjustment for age, smoking, and environmental exposure; thus, providing further support to the use of the CBMN assay as a highly predictive biomarker for lung cancer. To address the odds of lung cancer risk, we stratified by gender and smoking and found no differences in nonexposed male and female moderate smokers. For estimated risk of lung cancer, we found a difference between nonexposed male heavy smokers and nonexposed female heavy smokers, although it was not statistically significant (I2 = 64.9%; P value for Q statistic = 0.09). Because of the subgroup analyses and issues with multiple comparisons, chance variability may account for such findings. However, other factors such as interindividual differences in the genetic susceptibility and other coexposures may also play a role.

According to the 2012 American Cancer Society estimates, cancer of the lung and bronchus in both males and females each represent 14% of the new cancer diagnoses in the United States (116,470 and 109,690, respectively). Although the incidence rate in males has been decreasing since the mid-1980s, the incidence rate in females has just begun to decrease. Between 2004 and 2008 the incidence rate in males decreased by 1.9% per year, whereas the rate in females has only decreased by 0.3% per year (45).

In terms of cancer risk, the concept that females have an increased risk of lung cancer compared with males remains debatable. Several studies have reported that females exhibit an excess risk of lung cancer (46–48); however, other studies refute these findings (49–55). In a recent study in never smokers, Lo and colleagues (56) found males with a family history of lung cancer in first degree relatives had a slightly higher increased risk as compared with females with a family history of lung cancer in first-degree relatives. However, in the same study, females with a history of hormone replacement therapy (HRT) displayed a protective effect, thus suggesting hormonal differences in the development of lung cancer.

The obvious biologic differences between males and females are hormonal, yet the role of HRT and risk of lung cancer remains controversial (57). Studies have shown a decreased risk (58–63), whereas others have shown an increased risk of lung cancer (64–68). However, evidence for the role of estrogen receptors (ER) in human lung studies is rapidly accumulating and providing evidence on the role of ERs (ER-α and ER-β) in the pathogenesis of lung cancer (68). Both ER-α and ER-β have been shown in lung cancer tissue and cell lines and could hypothetically contribute to lung carcinogenesis (69–79). Although biologic differences between the sexes remain unequivocal, lung cancer development may also be attributed to areas such as growth factor receptors mutagen sensitivity, and differences in DNA repair capacity (80, 81).

Because only 10% to 15% of long-term smokers develop lung cancer in their lifetime, it is believed that genetic variation in sensitivity to carcinogen induced damage, as well as variation in DNA damage and repair capacity, may play a critical role in the development of lung cancer (82–84). DNA repair is a critical biologic defense mechanism that maintains the strength of the human genome by repairing damage from endogenous and exogenous sources (82). Wei and colleagues (85) were among the first to show an association between suboptimal DNA repair and an increased risk in lung cancer. Their findings were later confirmed in other studies (82, 86), which additionally found that pack-years smoked was also an independent predictor of lung cancer risk and further noted higher DNA repair in heavier smoking cases and lower repair in women compared with men (86).

Hill and colleagues (87) investigated gender differences in genetic damage induced by tobacco-specific nitrosamine (NNK), using the mutagen-sensitivity assay, which reflects an individual's sensitivity to mutagens as well as measures the DNA repair capacity in the individual (88). Although we did not find a difference in the number of chromosome aberrations between males and females in our study, their findings that chromosome aberrations were higher in females than in males (P = 0.02) support the idea that such biologic differences may contribute to the increase in lung cancer among females. Further their data suggest that a female's reduced capacity for repair of NNK-induced genetic damage may make them more sensitive to the mutagen effects (87). Considering the biologic differences between the sexes helps substantiate our finding that female heavy smokers exhibited an increased odds of lung cancer when compared with their male heavy smoker counterparts and could be due, in part, to suboptimal DNA repair. However, it does not explain why we found nonexposed female heavy smokers had an over a 4-fold increased risk of lung cancer compared with all other categories of female participants, including exposed females.

In our test for heterogeneity, we did not find a statistically significant difference between female heavy smokers (OR = 2.67; 95% CI, 1.39–5.11) and female moderate smokers (OR = 3.71; 95% CI, 1.78–7.70; I2 = 4.4%; P value for Q statistic = 0.31) with exposure, however, our statistically significant test for trend in this category (Ptrend = 0.027) gives us pause to reflect on why the trend reverses between the moderate and heavy smokers. The concept that a low level of an exposure is deleterious at higher levels and confers a protective effect, also known as the Hormesis Hypothesis, introduces a novel concept that may explain our intriguing findings. Hormetic responses occur at the cellular, organ, individual, and population levels and reflect a general response to environmental induced stress/damage in which low/modest stress induces a prosurvival response (88). Given our results, we speculate that long-term [chronic] exposure to tobacco smoke and environmental agents may act hormetically to up regulate on the DNA repair mechanisms, and thus decrease the risk of lung cancer.

Hormesis is a conceptual model used to characterize a dose–response relationship between a chemical dose and a biologic response. Hormesis uses a U-shaped dose–response relationship to represent an initial protective effect at low exposure concentrations due to overcompensation to a disruption in homeostasis (89). Wang and colleagues (90) found that at low concentrations BDE-47 promoted cell proliferation with no obvious DNA damage or cell apoptosis, whereas at high concentrations BDE-47 inhibited cell proliferation and induced reactive oxygen species (ROS) production, which can lead to apoptosis.

In our study, we cannot rule out the suggestion that long-term, low levels of an environmental exposure could act hormetically with heavy smoking to decrease the risk of lung cancer in females and might explain the differences we found between exposed females who are moderate and heavy smokers. Several studies reported that heavy smokers have a more robust repair capacity (85, 91). In a recent study using data from the diesel exhaust in miners study (DEMS), Silverman and colleagues (92) evaluated exposure to diesel exhaust and lung cancer mortality in a nested case–control setting and found a similar association between smoking intensity and attenuated risk of lung cancer. Among the heaviest smoking participants, lung cancer risk decreased with increased levels of diesel exposure and the risk associated with smoking intensity was modified by diesel exposure. As with our study, the authors speculate that these findings may be due to biologic responses such as more efficient DNA repair, enhanced detoxification, or saturation of metabolic activation (92).

Limitations in our study necessitate consideration. First, we used a hospital-based case recruitment system, therefore, our study is not population-based and selection bias may occur. Second, we were not able to measure environmental exposure quantitatively. Environmental exposure was based on a self-reported ever or never response, and therefore recall and reporting bias is a possibility. That said, several studies have validated the use of self-report as a viable means for assessing chemical-related exposures (93–95). Thus, if misclassification of exposure occurred it would be nondifferential and bias the risk of lung cancer toward the null (96). Arguably the strength of this study is that it confirms, in a larger sample size with measured smoking intensity, the CBMN assay is a rapid and accurate predictor of lung cancer. Moreover, our study further supports the premise that heavy smoking may have an effect on DNA repair capacity and in turn modulate the risk of lung cancer. The recent findings from the first study with quantitative data on historical diesel exposure and an adequate sample size to evaluate an exposure–response relationship between diesel exhaust, smoking intensity, and risk of lung cancer support our findings. Future studies are needed to confirm and determine the underlying mechanisms involved in the observed gender differences and risk of lung cancer.

C.J. Etzel has Ownership Interest (including patents) in Patent on CBMN assay. No potential conflicts of interest were disclosed by the other authors.

Conception and design: M.K. McHugh, M.R. Spitz, C.J. Etzel, R.A. El-Zein

Development of methodology: M.K. McHugh, M.S. Lopez, M.R. Spitz, C.J. Etzel, R.A. El-Zein

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.S. Lopez, M.R. Spitz, R.A. El-Zein

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.K. McHugh, C.-H. Ho, M.R. Spitz, R.A. El-Zein

Writing, review, and/or revision of the manuscript: M.K. McHugh, M.R. Spitz, C.J. Etzel, R.A. El-Zein

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.S. Lopez, M.R. Spitz, R.A. El-Zein

Study supervision: M.R. Spitz, C.J. Etzel, R.A. El-Zein

The authors thank Dr. Terrance J. Kavanagh at the University of Washington, Department of Environmental and Occupational Health Sciences for his insightful comments.

This work was supported by the National Cancer Institute at the NIH (K07CA093592 to C.J. Etzel, CA55769 and CA127219 to M.R. Spitz, and CA123208 and CA131327 to C.J. Etzel), and by a National Cancer Institute at the NIH cancer prevention fellowship (R25T CA57730 to M.K. McHugh).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Checkoway
H
,
Pearce
N
,
Kriebel
D
. 
Research methods in occupational epidemiology
. 2nd ed.
Oxford, UK
:
Oxford University Press
; 
2004
.
2.
Sailaja
N
,
Chandrasekhar
M
,
Rekhadevi
PV
,
Mahboob
M
,
Rahman
MF
,
Vuyyuri
SB
, et al
Genotoxic evaluation of workers employed in pesticide production
.
Mutat Res
2006
;
609
:
74
80
.
3.
Atherton
KM
,
Williams
FM
,
Egea
Gonzalez FJ
,
Glass
R
,
Rushton
S
,
Blain
PG
, et al
DNA damage in horticultural farmers: a pilot study showing an association with organophosphate pesticide exposure
.
Biomarkers
2009
;
14
:
443
51
.
4.
Zeljezic
D
,
Vrdoljak
AL
,
Lucas
JN
,
Lasan
R
,
Fucic
A
,
Kopjar
N
, et al
Effect of occupational exposure to multiple pesticides on translocation yield and chromosomal aberrations in lymphocytes of plant workers
.
Environ Sci Technol
2009
;
43
:
6370
7
.
5.
Hengstler
JG
,
Bolm-Audorff
U
,
Faldum
A
,
Janssen
K
,
Reifenrath
M
,
Gotte
W
, et al
Occupational exposure to heavy metals: DNA damage induction and DNA repair inhibition prove co-exposures to cadmium, cobalt and lead as more dangerous than hitherto expected
.
Carcinogenesis
2003
;
24
:
63
73
.
6.
Palus
J
,
Rydzynski
K
,
Dziubaltowska
E
,
Wyszynska
K
,
Natarajan
AT
,
Nilsson
R
. 
Genotoxic effects of occupational exposure to lead and cadmium
.
Mutat Res
2003
;
540
:
19
28
.
7.
Danadevi
K
,
Rozati
R
,
Saleha
Banu B
,
Hanumanth
Rao P
,
Grover
P
. 
DNA damage in workers exposed to lead using comet assay
.
Toxicology
2003
;
187
:
183
93
.
8.
Cebulska-Wasilewska
A
,
Panek
A
,
Zabinski
Z
,
Moszczynski
P
,
Au
WW
. 
Occupational exposure to mercury vapour on genotoxicity and DNA repair
.
Mutat Res
2005
;
586
:
102
14
.
9.
Vodicka
P
,
Koskinen
M
,
Stetina
R
,
Soucek
P
,
Vodickova
L
,
Matousu
Z
, et al
The role of various biomarkers in the evaluation of styrene genotoxicity
.
Cancer Detect Prev
2003
;
27
:
275
84
.
10.
Slyskova
J
,
Dusinska
M
,
Kuricova
M
,
Soucek
P
,
Vodickova
L
,
Susova
S
, et al
Relationship between the capacity to repair 8-oxoguanine, biomarkers of genotoxicity and individual susceptibility in styrene-exposed workers
.
Mutat Res
2007
;
634
:
101
11
.
11.
Vodicka
P
,
Tvrdik
T
,
Osterman-Golkar
S
,
Vodickova
L
,
Peterkova
K
,
Soucek
P
, et al
An evaluation of styrene genotoxicity using several biomarkers in a 3-year follow-up study of hand-lamination workers
.
Mutat Res
1999
;
445
:
205
24
.
12.
Manini
P
,
De Palma
G
,
Andreoli
R
,
Marczynski
B
,
Hanova
M
,
Mozzoni
P
, et al
Biomarkers of nucleic acid oxidation, polymorphism in, and expression of, hOGG1 gene in styrene-exposed workers
.
Toxicol Lett
2009
;
190
:
41
7
.
13.
Maffei
F
,
Angelini
S
,
Forti
GC
,
Violante
FS
,
Lodi
V
,
Mattioli
S
, et al
Spectrum of chromosomal aberrations in peripheral lymphocytes of hospital workers occupationally exposed to low doses of ionizing radiation
.
Mutat Res
2004
;
547
:
91
9
.
14.
Kopjar
N
,
Garaj-Vrhovac
V
. 
Assessment of DNA damage in nuclear medicine personnel—comparative study with the alkaline comet assay and the chromosome aberration test
.
Int J Hyg Environ Health
2005
;
208
:
179
91
.
15.
Jovicic
D
,
Milacic
S
,
Milic
N
,
Bukvic
N
,
Vukov
TD
. 
Chromosomal aberrations in subjects exposed to ionizing radiation
.
J Environ Pathol Toxicol Oncol
2009
;
28
:
75
82
.
16.
Lalic
H
. 
Cytogenetic monitoring of medical staff professionally exposed to Gamma and X radiation
.
Neoplasma
2005
;
52
:
307
13
.
17.
Engin
AB
,
Ergun
MA
,
Yurtcu
E
,
Kan
D
,
Sahin
G
. 
Effect of ionizing radiation on the pteridine metabolic pathway and evaluation of its cytotoxicity in exposed hospital staff
.
Mutat Res
2005
;
585
:
184
92
.
18.
Galiotte
MP
,
Kohler
P
,
Mussi
G
,
Gattas
GJ
. 
Assessment of occupational genotoxic risk among Brazilian hairdressers
.
Ann Occup Hyg
2008
;
52
:
645
51
.
19.
Costa
S
,
Coelho
P
,
Costa
C
,
Silva
S
,
Mayan
O
,
Santos
LS
, et al
Genotoxic damage in pathology anatomy laboratory workers exposed to formaldehyde
.
Toxicology
2008
;
252
:
40
8
.
20.
Cavallo
D
,
Ursini
CL
,
Setini
A
,
Chianese
C
,
Cristaudo
A
,
Iavicoli
S
. 
DNA damage and TNFalpha cytokine production in hairdressers with contact dermatitis
.
Contact Dermatitis
2005
;
53
:
125
9
.
21.
Ursini
CL
,
Cavallo
D
,
Colombi
A
,
Giglio
M
,
Marinaccio
A
,
Iavicoli
S
. 
Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs
.
Int Arch Occup Environ Health
2006
;
80
:
134
40
.
22.
Sasaki
M
,
Dakeishi
M
,
Hoshi
S
,
Ishii
N
,
Murata
K
. 
Assessment of DNA damage in Japanese nurses handling antineoplastic drugs by the comet assay
.
J Occup Health
2008
;
50
:
7
12
.
23.
Rekhadevi
PV
,
Sailaja
N
,
Chandrasekhar
M
,
Mahboob
M
,
Rahman
MF
,
Grover
P
. 
Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs
.
Mutagenesis
2007
;
22
:
395
401
.
24.
Consonni
D
,
Boffetta
P
,
Andersen
A
,
Chang-Claude
J
,
Cherrie
JW
,
Ferro
G
, et al
Lung cancer mortality among European rock/slag wool workers: exposure-response analysis
.
Cancer Causes Control
1998
;
9
:
411
6
.
25.
Chiazze
L
 Jr
,
Watkins
DK
. 
Epidemiology studies of synthetic vitreous fibers: methods used and current studies
.
Regul Toxicol Pharmacol
1994
;
20
(
3 Pt 2
):
S58
67
.
26.
Chiazze
L
 Jr
,
Watkins
DK
,
Fryar
C
. 
Adjustment for the confounding effect of cigarette smoking in an historical cohort mortality study of workers in a fiberglass manufacturing facility
.
J Occup Environ Med
1995
;
37
:
744
8
.
27.
Wong
O
,
Musselman
RP
. 
An epidemiological and toxicological evaluation of the carcinogenicity of man-made vitreous fiber, with a consideration of coexposures
.
J Environ Pathol Toxicol Oncol
1994
;
13
:
169
80
.
28.
Berrigan
D
. 
Respiratory cancer and exposure to man-made vitreous fibers: a systematic review
.
Am J Ind Med
2002
;
42
:
354
62
.
29.
Ross
NA
,
Wolfson
MC
,
Dunn
JR
,
Berthelot
JM
,
Kaplan
GA
,
Lynch
JW
. 
Relation between income inequality and mortality in Canada and in the United States: cross sectional assessment using census data and vital statistics
.
BMJ
2000
;
320
:
898
902
.
30.
El-Zein
R
,
Vral
A
,
Etzel
CJ
. 
Cytokinesis-blocked micronucleus assay and cancer risk assessment
.
Mutagenesis
2011
;
26
:
101
6
.
31.
Christmann
M
,
Tomicic
MT
,
Roos
WP
,
Kaina
B
. 
Mechanisms of human DNA repair: an update
.
Toxicology
2003
;
193
:
3
34
.
32.
Fenech
M
. 
Biomarkers of genetic damage for cancer epidemiology
.
Toxicology
2002
;
181–182
:
411
6
.
33.
Fenech
M
. 
The in vitro micronucleus technique
.
Mutat Res
2000
;
455
:
81
95
.
34.
El-Zein
RA
,
Schabath
MB
,
Etzel
CJ
,
Lopez
MS
,
Franklin
JD
,
Spitz
MR
. 
Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk
.
Cancer Res
2006
;
66
:
6449
56
.
35.
El-Zein
RA
,
Fenech
M
,
Lopez
MS
,
Spitz
MR
,
Etzel
CJ
. 
Cytokinesis-blocked micronucleus cytome assay biomarkers identify lung cancer cases amongst smokers
.
Cancer Epidemiol Biomarkers Prev
2008
;
17
:
1111
9
.
36.
McHugh
MK
,
Kachroo
S
,
Liu
M
,
D'Amelio
AM
 Jr
,
Dong
Q
,
Hong
WK
, et al
Assessing environmental and occupational risk factors for lung cancer in Mexican-Americans
.
Cancer Causes Control
2010
;
21
:
2157
64
.
37.
Spitz
MR
,
Hong
WK
,
Amos
CI
,
Wu
X
,
Schabath
MB
,
Dong
Q
, et al
A risk model for prediction of lung cancer
.
J Natl Cancer Inst
2007
;
99
:
715
26
.
38.
Etzel
CJ
,
Kachroo
S
,
Liu
M
,
D'Amelio
A
,
Dong
Q
,
Cote
ML
, et al
Development and validation of a lung cancer risk prediction model for African–Americans
.
Cancer Prev Res
2008
;
1
:
255
65
.
39.
Fenech
M
,
Morley
AA
. 
Measurement of micronuclei in lymphocytes
.
Mutat Res
1985
;
147
:
29
36
.
40.
Fenech
M
. 
Cytokinesis-block micronucleus cytome assay
.
Nat Protoc
2007
;
2
:
1084
104
.
41.
Fenech
M
. 
Micronucleus frequency in human lymphocytes is related to plasma vitamin B12 and homocysteine
.
Mutat Res
1999
;
428
:
299
304
.
42.
Fenech
M
,
Chang
WP
,
Kirsch-Volders
M
,
Holland
N
,
Bonassi
S
,
Zeiger
E
. 
HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures
.
Mutat Res
2003
;
534
:
65
75
.
43.
Jollie
IT
. 
Principle component analysis
.
New York
:
Springer
; 
2002
.
44.
Higgins
JP
,
Thompson
SG
,
Deeks
JJ
,
Altman
DG
. 
Measuring inconsistency in meta-analyses
.
BMJ
2003
;
327
:
557
60
.
45.
American Cancer Society
. 
Cancer facts and figures 2012
. 
2012
[cited 2012 Mar 2]. Available from
: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012.
46.
Brownson
RC
,
Chang
JC
,
Davis
JR
. 
Gender and histologic type variations in smoking-related risk of lung cancer
.
Epidemiology
1992
;
3
:
61
4
.
47.
Risch
HA
,
Howe
GR
,
Jain
M
,
Burch
JD
,
Holowaty
EJ
,
Miller
AB
. 
Are female smokers at higher risk for lung cancer than male smokers? A case–control analysis by histologic type
.
Am J Epidemiol
1993
;
138
:
281
93
.
48.
Zang
EA
,
Wynder
EL
. 
Differences in lung cancer risk between men and women: examination of the evidence
.
J Natl Cancer Inst
1996
;
88
:
183
92
.
49.
Henschke
CI
,
Yip
R
,
Miettinen
OS
. 
Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer
.
JAMA
2006
;
296
:
180
4
.
50.
Prescott
E
,
Osler
M
,
Hein
HO
,
Borch-Johnsen
K
,
Lange
P
,
Schnohr
P
, et al
Gender and smoking-related risk of lung cancer. The Copenhagen Center for Prospective Population Studies
.
Epidemiology
1998
;
9
:
79
83
.
51.
Halpern
MT
,
Gillespie
BW
,
Warner
KE
. 
Patterns of absolute risk of lung cancer mortality in former smokers
.
J Natl Cancer Inst
1993
;
85
:
457
64
.
52.
Bain
C
,
Feskanich
D
,
Speizer
FE
,
Thun
M
,
Hertzmark
E
,
Rosner
BA
, et al
Lung cancer rates in men and women with comparable histories of smoking
.
J Natl Cancer Inst
2004
;
96
:
826
34
.
53.
Bach
PB
,
Kattan
MW
,
Thornquist
MD
,
Kris
MG
,
Tate
RC
,
Barnett
MJ
, et al
Variations in lung cancer risk among smokers
.
J Natl Cancer Inst
2003
;
95
:
470
8
.
54.
Agudo
A
,
Ahrens
W
,
Benhamou
E
,
Benhamou
S
,
Boffetta
P
,
Darby
SC
, et al
Lung cancer and cigarette smoking in women: a multicenter case–control study in Europe
.
Int J Cancer
2000
;
88
:
820
7
.
55.
Kreuzer
M
,
Boffetta
P
,
Whitley
E
,
Ahrens
W
,
Gaborieau
V
,
Heinrich
J
, et al
Gender differences in lung cancer risk by smoking: a multicentre case–control study in Germany and Italy
.
Br J Cancer
2000
;
82
:
227
33
.
56.
Lo
YL
,
Hsiao
CF
,
Chang
GC
,
Tsai
YH
,
Huang
MS
,
Su
WC
, et al
Risk factors for primary lung cancer among never smokers by gender in a matched case–control study
.
Cancer Causes Control
. 
2012
May 22.
[Epub ahead of print]
.
57.
Chakraborty
S
,
Ganti
AK
,
Marr
A
,
Batra
SK
. 
Lung cancer in women: role of estrogens
.
Expert Rev Respir Med
2010
;
4
:
509
18
.
58.
Schabath
MB
,
Wu
X
,
Vassilopoulou-Sellin
R
,
Vaporciyan
AA
,
Spitz
MR
. 
Hormone replacement therapy and lung cancer risk: a case–control analysis
.
Clin Cancer Res
2004
;
10
(
1 Pt 1
):
113
23
.
59.
Ramnath
N
,
Menezes
RJ
,
Loewen
G
,
Dua
P
,
Eid
F
,
Alkhaddo
J
, et al
Hormone replacement therapy as a risk factor for non–small cell lung cancer: results of a case–control study
.
Oncology
2007
;
73
:
305
10
.
60.
Schwartz
AG
,
Wenzlaff
AS
,
Prysak
GM
,
Murphy
V
,
Cote
ML
,
Brooks
SC
, et al
Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women
.
J Clin Oncol
2007
;
25
:
5785
92
.
61.
Chen
KY
,
Hsiao
CF
,
Chang
GC
,
Tsai
YH
,
Su
WC
,
Perng
RP
, et al
Hormone replacement therapy and lung cancer risk in Chinese
.
Cancer
2007
;
110
:
1768
75
.
62.
Blackman
JA
,
Coogan
PF
,
Rosenberg
L
,
Strom
BL
,
Zauber
AG
,
Palmer
JR
, et al
Estrogen replacement therapy and risk of lung cancer
.
Pharmacoepidemiol Drug Saf
2002
;
11
:
561
7
.
63.
Kreuzer
M
,
Gerken
M
,
Heinrich
J
,
Kreienbrock
L
,
Wichmann
HE
. 
Hormonal factors and risk of lung cancer among women?
Int J Epidemiol
2003
;
32
:
263
71
.
64.
Taioli
E
,
Wynder
EL
. 
Re: endocrine factors and adenocarcinoma of the lung in women
.
J Natl Cancer Inst
1994
;
86
:
869
70
.
65.
Adami
HO
,
Persson
I
,
Hoover
R
,
Schairer
C
,
Bergkvist
L
. 
Risk of cancer in women receiving hormone replacement therapy
.
Int J Cancer
1989
;
44
:
833
9
.
66.
Smith
JR
,
Barrett-Connor
E
,
Kritz-Silverstein
D
,
Wingard
DL
,
Al-Delaimy
WK
. 
Hormone use and lung cancer incidence: the Rancho Bernardo cohort study
.
Menopause
2009
;
16
:
1044
8
.
67.
Slatore
CG
,
Chien
JW
,
Au
DH
,
Satia
JA
,
White
E
. 
Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study
.
J Clin Oncol
2010
;
28
:
1540
6
.
68.
Chlebowski
RT
,
Schwartz
AG
,
Wakelee
H
,
Anderson
GL
,
Stefanick
ML
,
Manson
JE
, et al
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial
.
Lancet
2009
;
374
:
1243
51
.
69.
Fasco
MJ
,
Hurteau
GJ
,
Spivack
SD
. 
Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue
.
Mol Cell Endocrinol
2002
;
188
:
125
40
.
70.
Omoto
Y
,
Kobayashi
Y
,
Nishida
K
,
Tsuchiya
E
,
Eguchi
H
,
Nakagawa
K
, et al
Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers
.
Biochem Biophys Res Commun
2001
;
285
:
340
7
.
71.
Kawai
H
,
Ishii
A
,
Washiya
K
,
Konno
T
,
Kon
H
,
Yamaya
C
, et al
Estrogen receptor alpha and beta are prognostic factors in non–small cell lung cancer
.
Clin Cancer Res
2005
;
11
:
5084
9
.
72.
Ishibashi
H
,
Suzuki
T
,
Suzuki
S
,
Niikawa
H
,
Lu
L
,
Miki
Y
, et al
Progesterone receptor in non–small cell lung cancer—a potent prognostic factor and possible target for endocrine therapy
.
Cancer Res
2005
;
65
:
6450
8
.
73.
Marquez-Garban
DC
,
Chen
HW
,
Fishbein
MC
,
Goodglick
L
,
Pietras
RJ
. 
Estrogen receptor signaling pathways in human non–small cell lung cancer
.
Steroids
2007
;
72
:
135
43
.
74.
Schwartz
AG
,
Prysak
GM
,
Murphy
V
,
Lonardo
F
,
Pass
H
,
Schwartz
J
, et al
Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex
.
Clin Cancer Res
2005
;
11
:
7280
7
.
75.
Kaiser
U
,
Hofmann
J
,
Schilli
M
,
Wegmann
B
,
Klotz
U
,
Wedel
S
, et al
Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer
.
Int J Cancer
1996
;
67
:
357
64
.
76.
Weinberg
OK
,
Marquez-Garban
DC
,
Fishbein
MC
,
Goodglick
L
,
Garban
HJ
,
Dubinett
SM
, et al
Aromatase inhibitors in human lung cancer therapy
.
Cancer Res
2005
;
65
:
11287
91
.
77.
Stabile
LP
,
Davis
AL
,
Gubish
CT
,
Hopkins
TM
,
Luketich
JD
,
Christie
N
, et al
Human non–small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen
.
Cancer Res
2002
;
62
:
2141
50
.
78.
Hershberger
PA
,
Vasquez
AC
,
Kanterewicz
B
,
Land
S
,
Siegfried
JM
,
Nichols
M
. 
Regulation of endogenous gene expression in human non–small cell lung cancer cells by estrogen receptor ligands
.
Cancer Res
2005
;
65
:
1598
605
.
79.
Radzikowska
E
,
Langfort
R
,
Giedronowicz
D
. 
Estrogen and progesterone receptors in non small cell lung cancer patients
.
Ann Thorac Cardiovasc Surg
2002
;
8
:
69
73
.
80.
Rivera
MP
. 
Lung cancer in women: the differences in epidemiology, biology and treatment outcomes
.
Expert Rev Respir Med
2009
;
3
:
627
34
.
81.
Kiyohara
C
,
Ohno
Y
. 
Sex differences in lung cancer susceptibility: a review
.
Gend Med
2010
;
7
:
381
401
.
82.
Spitz
MR
,
Wei
Q
,
Dong
Q
,
Amos
CI
,
Wu
X
. 
Genetic susceptibility to lung cancer: the role of DNA damage and repair
.
Cancer Epidemiol Biomarkers Prev
2003
;
12
:
689
98
.
83.
Christiani
DC
. 
Smoking and the molecular epidemiology of lung cancer
.
Clin Chest Med
2000
;
21
:
87
93
.
84.
Li
D
,
Firozi
PF
,
Wang
LE
,
Bosken
CH
,
Spitz
MR
,
Hong
WK
, et al
Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: a case–control analysis
.
Cancer Res
2001
;
61
:
1445
50
.
85.
Wei
Q
,
Cheng
L
,
Amos
CI
,
Wang
LE
,
Guo
Z
,
Hong
WK
, et al
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study
.
J Natl Cancer Inst
2000
;
92
:
1764
72
.
86.
Shen
H
,
Spitz
MR
,
Qiao
Y
,
Guo
Z
,
Wang
LE
,
Bosken
CH
, et al
Smoking, DNA repair capacity and risk of nonsmall cell lung cancer
.
Int J Cancer
2003
;
107
:
84
8
.
87.
Hill
CE
,
Affatato
AA
,
Wolfe
KJ
,
Lopez
MS
,
Hallberg
CK
,
Canistro
D
, et al
Gender differences in genetic damage induced by the tobacco-specific nitrosamine NNK and the influence of the Thr241Met polymorphism in the XRCC3 gene
.
Environ Mol Mutagen
2005
;
46
:
22
9
.
88.
Calabrese
EJ
,
Iavicoli
I
,
Calabrese
V
. 
Hormesis: why it is important to biogerontologists
.
Biogerontology
2012
;
13
:
215
35
.
89.
Calabrese
EJ
,
Baldwin
LA
. 
The frequency of U-shaped dose responses in the toxicological literature
.
Toxicol Sci
2001
;
62
:
330
8
.
90.
Wang
L
,
Zou
W
,
Zhong
Y
,
An
J
,
Zhang
X
,
Wu
M
, et al
The hormesis effect of BDE-47 in HepG(2) cells and the potential molecular mechanism
.
Toxicol Lett
2012
;
209
:
193
201
.
91.
Deng
L
,
Kimmel
M
,
Foy
M
,
Spitz
M
,
Wei
Q
,
Gorlova
O
. 
Estimation of the effects of smoking and DNA repair capacity on coefficients of a carcinogenesis model for lung cancer
.
Int J Cancer
2009
;
124
:
2152
8
.
92.
Silverman
DT
,
Samanic
CM
,
Lubin
JH
,
Blair
AE
,
Stewart
PA
,
Vermeulen
R
, et al
The diesel exhaust in miners study: a nested case–control study of lung cancer and diesel exhaust
.
J Natl Cancer Inst
2012
;
104
:
1
14
.
93.
Koutros
S
,
Lynch
CF
,
Ma
X
,
Lee
WJ
,
Hoppin
JA
,
Christensen
CH
, et al
Heterocyclic aromatic amine pesticide use and human cancer risk: results from the U.S. Agricultural Health Study
.
Int J Cancer
2009
;
124
:
1206
12
.
94.
Blair
A
,
Tarone
R
,
Sandler
D
,
Lynch
CF
,
Rowland
A
,
Wintersteen
W
, et al
Reliability of reporting on life-style and agricultural factors by a sample of participants in the Agricultural Health Study from Iowa
.
Epidemiology
2002
;
13
:
94
9
.
95.
Hoppin
JA
,
Yucel
F
,
Dosemeci
M
,
Sandler
DP
. 
Accuracy of self-reported pesticide use duration information from licensed pesticide applicators in the Agricultural Health Study
.
J Expo Anal Environ Epidemiol
2002
;
12
:
313
8
.
96.
Rothman
KJ
,
Greenland
S
. 
Modern epidemiology
. 2nd ed.
Philadelphia, PA
:
Lippincott-Raven
; 
1998
.